My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1896

    1.

    One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

    Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

    Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

    Rachman J, Barrow BA, Levy JC, Turner RC.

    Diabetologia. 1997 Feb;40(2):205-11.PMID: 9049482 [PubMed - indexed for MEDLINE]Related articles

    5.

    Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

    Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S.

    Diabet Med. 2008 Feb;25(2):152-6. Epub 2008 Jan 14.PMID: 18201212 [PubMed - indexed for MEDLINE]Related articles

    6.

    The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

    Harder H, Nielsen L, Tu DT, Astrup A.

    Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

    Larsen J, Hylleberg B, Ng K, Damsbo P.

    Diabetes Care. 2001 Aug;24(8):1416-21.PMID: 11473079 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.

    Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M.

    Diabetes Care. 2002 Aug;25(8):1398-404.PMID: 12145241 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

    Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

    Diabet Med. 2005 Aug;22(8):1016-23.PMID: 16026367 [PubMed - indexed for MEDLINE]Related articles

    10.

    Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

    Diabetes. 1996 Nov;45(11):1524-30.PMID: 8866556 [PubMed - indexed for MEDLINE]Related articles

    11.

    The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

    Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB.

    Diabetes. 2003 Jul;52(7):1786-91.PMID: 12829647 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

    Zander M, Madsbad S, Madsen JL, Holst JJ.

    Lancet. 2002 Mar 9;359(9309):824-30.PMID: 11897280 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

    Ahrén B, Larsson H, Holst JJ.

    J Clin Endocrinol Metab. 1997 Feb;82(2):473-8.PMID: 9024239 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

    Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

    Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

    Clin Sci (Lond). 1998 Sep;95(3):325-9.PMID: 9730852 [PubMed - indexed for MEDLINE]Related articles

    16.

    Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

    Diabetes. 2001 Aug;50(8):1778-84.PMID: 11473038 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.

    Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B.

    J Intern Med. 2001 Jul;250(1):81-7.PMID: 11454146 [PubMed - indexed for MEDLINE]Related articles

    18.

    Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

    Toft-Nielsen MB, Madsbad S, Holst JJ.

    Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.

    Diabetes Care. 1996 Aug;19(8):857-63.PMID: 8842604 [PubMed - indexed for MEDLINE]Related articles

    20.

    Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

    Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25.PMID: 12788879 [PubMed - indexed for MEDLINE]Related articlesFree article

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity